NKX101
Acute Myeloid Leukemia / Higher-Risk MDS
Phase 1Active (likely deprioritized)
Key Facts
Indication
Acute Myeloid Leukemia / Higher-Risk MDS
Phase
Phase 1
Status
Active (likely deprioritized)
Company
About Nkarta
Nkarta is a clinical-stage biotech focused on developing engineered, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases and cancer. Its strategy centers on an allogeneic platform designed to overcome the manufacturing complexity and safety limitations of autologous cell therapies. The company has advanced its lead candidate, NKX019, into clinical trials for lupus nephritis and B-cell malignancies, supported by in-house GMP manufacturing capabilities and a strategic pivot emphasizing autoimmune indications.
View full company profile